Association of Obesity With Kidney and Cardiac Outcomes Among Patients With Glomerular Disease: Findings From the Cure Glomerulonephropathy Network

Overview

Journal Am J Kidney Dis

Specialty Nephrology

Date 2024 May 16

PMID 38750877

Authors

Evan M Zeitler

Dorey A Glenn

Yichun Hu

Ronald J Falk

Susan L Hogan

Amy K Mottl

Affiliations

Soon will be listed here.

Abstract

Rationale & Objective: The influence of obesity on cardiorenal outcomes in individuals with glomerular disease is incompletely known. This study examined the association between obesity and kidney and cardiovascular outcomes in children and adults with glomerular kidney disease.

Study Design: Prospective, multicenter, observational study.

Setting & Participants: Participants in the Cure Glomerulonephropathy Network (CureGN) who were≥5 years of age at enrollment.

Exposure: Adult body mass index (BMI) groups: 20-24 (healthy) versus 25-34 (overweight/class 1 obesity) versus≥35 (class 2-3 obesity); and pediatric BMI percentiles: 5th-84th (healthy) versus 85th-94th (overweight) versus≥95th (obese).

Outcome: A composite kidney outcome (40% estimated glomerular filtration rate [eGFR] decline or kidney failure) and a composite cardiovascular outcome (myocardial infarction, stroke, heart failure, or death).

Analytical Approach: Time to composite primary outcomes by BMI strata were estimated using Kaplan-Meier analysis. The adjusted associations between BMI and outcomes were estimated using Cox proportional hazards analysis.

Results: The study included 2,301 participants (1,548 adults and 753 children). The incidence of the primary kidney end point was 90.8 per 1,000 person-years in adults with class 2-3 obesity, compared with 58.0 in normal weight comparators. In the univariable analysis, class 2-3 obesity was associated with the primary kidney outcome only in adults (HR, 1.6 [95% CI, 1.1-2.2], P=0.006) compared with the healthy weight groups. In the multivariable adjusted analysis, class 2-3 obesity did not remain significant among adults when controlling for baseline eGFR and proteinuria. Adults with class 2-3 obesity had an incidence of 19.7 cardiovascular events per 1,000 person-years and greater cardiovascular risk (HR, 3.9 [95% CI, 1.4-10.7], P=0.009) in the fully adjusted model.

Limitations: BMI is an imperfect indicator of adiposity. Residual confounding may exist from socioeconomic factors.

Conclusions: Among adult patients in CureGN, class 2-3 obesity is associated with cardiovascular but not kidney outcomes when adjusted for potential confounding factors.

Plain-language Summary: Obesity is a risk factor for adverse heart and kidney outcomes in patients with chronic kidney disease, but whether it is associated with these outcomes in patients with glomerulonephropathy is not known. This study used existing data from a large sample of adults and children with glomerular diseases to address this question. The findings suggest that obesity increases the risk of cardiovascular but not kidney disease events in adult patients with glomerular disease.

References

Pierce C, Munoz A, Ng D, Warady B, Furth S, Schwartz G . Age- and sex-dependent clinical equations to estimate glomerular filtration rates in children and young adults with chronic kidney disease. Kidney Int. 2020; 99(4):948-956. PMC: 9083470. DOI: 10.1016/j.kint.2020.10.047. View

Barbour S, Cattran D, Kim S, Levin A, Wald R, Hladunewich M . Individuals of Pacific Asian origin with IgA nephropathy have an increased risk of progression to end-stage renal disease. Kidney Int. 2013; 84(5):1017-24. DOI: 10.1038/ki.2013.210. View

Heerspink H, Stefansson B, Correa-Rotter R, Chertow G, Greene T, Hou F . Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020; 383(15):1436-1446. DOI: 10.1056/NEJMoa2024816. View

Van Gaal L, Mertens I, De Block C . Mechanisms linking obesity with cardiovascular disease. Nature. 2006; 444(7121):875-80. DOI: 10.1038/nature05487. View

Marso S, Bain S, Consoli A, Eliaschewitz F, Jodar E, Leiter L . Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016; 375(19):1834-1844. DOI: 10.1056/NEJMoa1607141. View

Powell-Wiley T, Poirier P, Burke L, Despres J, Gordon-Larsen P, Lavie C . Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021; 143(21):e984-e1010. PMC: 8493650. DOI: 10.1161/CIR.0000000000000973. View

Lu J, Kalantar-Zadeh K, Ma J, Quarles L, Kovesdy C . Association of body mass index with outcomes in patients with CKD. J Am Soc Nephrol. 2014; 25(9):2088-96. PMC: 4147974. DOI: 10.1681/ASN.2013070754. View

Griffin K, Kramer H, Bidani A . Adverse renal consequences of obesity. Am J Physiol Renal Physiol. 2008; 294(4):F685-96. DOI: 10.1152/ajprenal.00324.2007. View

Docherty N, le Roux C . Bariatric surgery for the treatment of chronic kidney disease in obesity and type 2 diabetes mellitus. Nat Rev Nephrol. 2020; 16(12):709-720. DOI: 10.1038/s41581-020-0323-4. View

10.

Wu C, Wang A, Li G, Wang L . Association of high body mass index with development of interstitial fibrosis in patients with IgA nephropathy. BMC Nephrol. 2018; 19(1):381. PMC: 6310977. DOI: 10.1186/s12882-018-1164-2. View

11.

Chang A, Zafar W, Grams M . Kidney Function in Obesity-Challenges in Indexing and Estimation. Adv Chronic Kidney Dis. 2018; 25(1):31-40. PMC: 5836495. DOI: 10.1053/j.ackd.2017.10.007. View

12.

Shah P, Brady T, Meyers K, OShaughnessy M, Gibson K, Srivastava T . Association of Obesity with Cardiovascular Risk Factors and Kidney Disease Outcomes in Primary Proteinuric Glomerulopathies. Nephron. 2021; 145(3):245-255. PMC: 8102330. DOI: 10.1159/000513869. View

13.

Shaman A, Bain S, Bakris G, Buse J, Idorn T, Mahaffey K . Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER. Circulation. 2021; 145(8):575-585. PMC: 8860212. DOI: 10.1161/CIRCULATIONAHA.121.055459. View

14.

Inker L, Eneanya N, Coresh J, Tighiouart H, Wang D, Sang Y . New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. N Engl J Med. 2021; 385(19):1737-1749. PMC: 8822996. DOI: 10.1056/NEJMoa2102953. View

15.

Yonekura Y, Goto S, Sugiyama H, Kitamura H, Yokoyama H, Nishi S . The influences of larger physical constitutions including obesity on the amount of urine protein excretion in primary glomerulonephritis: research of the Japan Renal Biopsy Registry. Clin Exp Nephrol. 2014; 19(3):359-70. DOI: 10.1007/s10157-014-0993-y. View

16.

Ashoor I, Mansfield S, OShaughnessy M, Parekh R, Zee J, Vasylyeva T . Prevalence of Cardiovascular Disease Risk Factors in Childhood Glomerular Diseases. J Am Heart Assoc. 2019; 8(14):e012143. PMC: 6662122. DOI: 10.1161/JAHA.119.012143. View

17.

Herrington W, Staplin N, Wanner C, Green J, Hauske S, Emberson J . Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2022; 388(2):117-127. PMC: 7614055. DOI: 10.1056/NEJMoa2204233. View

18.

Choung H, Bomback A, Stokes M, Santoriello D, Campenot E, Batal I . The spectrum of kidney biopsy findings in patients with morbid obesity. Kidney Int. 2019; 95(3):647-654. DOI: 10.1016/j.kint.2018.11.026. View

19.

Elyan B, Lees J, Gillis K, Mackinnon B, Fox J, Geddes C . Obesity is not associated with progression to end stage renal disease in patients with biopsy-proven glomerular diseases. BMC Nephrol. 2019; 20(1):237. PMC: 6604373. DOI: 10.1186/s12882-019-1434-7. View

20.

Tuttle K, Lakshmanan M, Rayner B, Busch R, Zimmermann A, Woodward D . Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 2018; 6(8):605-617. DOI: 10.1016/S2213-8587(18)30104-9. View